Hold the tablet with your thumbs placed close to the scored part of the tablet (groove). The conjugates can also be deconjugated in the ileum by intestinal enzymes, leading to the formation of free Ursodiol that can be reabsorbed and reconjugated in the liver. At a chronic dose of 13 to 15 mg/kg/day, Ursodiol constitutes 30 to 50% of biliary and plasma bile acids.In two 24-month oral carcinogenicity studies in mice, Ursodiol at doses up to 1,000 mg/kg/day (3,000 mg/mIn a two-year oral carcinogenicity study in Fischer 344 rats, Ursodiol at doses up to 300 mg/kg/day (1,800 mg/mIn a life-span (126 to 138 weeks) oral carcinogenicity study, Sprague-Dawley rats were treated with doses of 33 to 300 mg/kg/day, 0.4 to 3.2 times the recommended maximum human dose based on body surface area.Ursodiol produced a significantly (p≤0.5, Fisher's exact test) increased incidence of pheochromocytomas of the adrenal medulla in females of the highest dose group.In 103-week oral carcinogenicity studies of lithocholic acid, a metabolite of Ursodiol, doses up to 250 mg/kg/day in mice and 500 mg/kg/day in rats did not produce any tumors. As the severity of liver disease increases, the extent of extraction decreases. These symptoms may mean that you have other medical problems or that your gallstone condition needs your doctor's attention.Do not take other medicines unless they have been discussed with your doctor.
Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.It is not known whether Ursodiol is excreted in human milk. After two years of double-blind treatment, the incidence of treatment failure was significantly (p<0.01) reduced in the Ursodiol 250 mg group (20 of 86 (23%)) as compared to the placebo group (40 of 86 (47%)).
General disorders and administration site conditions:We comply with the HONcode standard for trustworthy health information - Also remember when doing any cleanse--drink lots of water.
The resulting sulfated lithocholic acid conjugates are excreted in bile and then lost in feces.
Its volume of distribution has not been determined, but is expected to be small since the drug is mostly distributed in the bile and small intestine. even though they are not marketed as dispersible. Symptoms of acute toxicity were salivation and vomiting in dogs, and ataxia, dyspnea, ptosis, agonal convulsions and coma in hamsters.Ursodiol Tablets, USP 250 mg are available as a film-coated tablet for oral administration. Ursodiol Tablets, USP 500 mg are available as a scored film-coated tablet for oral administration. Therefore, death, need for liver transplantation, histological progression by two stages or to cirrhosis, development of varices, ascites or encephalopathy, marked worsening of fatigue or pruritus, inability to tolerate the drug, doubling of serum bilirubin and voluntary withdrawal were not assessed.A randomized, two-period crossover study in fifty PBC patients compared efficacy of Ursodiol 250 mg in twice a day versus four times a day divided dosing schedules in 50 patients for 6 months in each crossover period.
Nonabsorbed Ursodiol passes into the colon where it is mostly 7-dehydroxylated to lithocholic acid.
Patients with complete biliary obstruction and known hypersensitivity or intolerance to Ursodiol or any of the components of the formulation.Patients with variceal bleeding, hepatic encephalopathy, ascites or in need of an urgent liver transplant, should receive appropriate specific treatment.Caution has to be exercised to maintain the bile flow of the patients taking Ursodiol.Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.The following table summarizes the adverse reactions observed in two placebo-controlled clinical trials.Note: Those adverse reactions occurring at the same or higher incidence in the placebo as in the UDCA group have been deleted from this table (this includes diarrhea and thrombocytopenia at 12 months, nausea/vomiting, fever and other toxicity).In a randomized, cross-over study in sixty PBC patients, seven patients (11.6%) reported nine adverse reactions: abdominal pain and asthenia (1 patient), nausea (3 patients), dyspepsia (2 patients) and anorexia and esophagitis (1 patient each).
All of these nine adverse reactions except esophagitis were observed with the twice a day regimen at a total daily dose of 1,000 mg or greater.